<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629443</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-64315-004</org_study_id>
    <secondary_id>2019-004896-38</secondary_id>
    <nct_id>NCT04629443</nct_id>
  </id_info>
  <brief_title>Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia</brief_title>
  <official_title>Phase I/II, International, Multicentre, Open-label, Non-randomised, Non-comparative, Study Evaluating the Safety, Tolerability and Clinical Activity of Intravenously Administered S64315, a Selective Mcl-1 Inhibitor, in Combination With Azacitidine in Patients With Acute Myeloid Leukaemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and clinical activity of the&#xD;
      combination S64315 with azacitidine in patients with acute myeloid leukaemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) (Phase I - dose escalation)</measure>
    <time_frame>Day -13 to Cycle 1 Day 28 (each cycle is 28 days)</time_frame>
    <description>Incidence of DLTs starting from the Lead-In Dose period to the end of the first cycle of treatment of S64315 in combination with azacitidine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events (AEs) (Phase I - dose escalation)</measure>
    <time_frame>an average of 6 months</time_frame>
    <description>Incidence and severity of AEs and SAEs according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Serious Adverse Event (SAEs) (Phase I - dose escalation)</measure>
    <time_frame>Day -13 up to 30 calendar days after the patient's last study visit</time_frame>
    <description>Incidence and severity of SAEs according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose interruptions (Phase I - dose escalation)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose reductions (Phase I - dose escalation)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity (Phase I - dose escalation)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess anti-leukemic activity of S64315 in combinaison with azacitidine (Phase I - dose escalation)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess anti-leukemic activity of S64315 in combinaison with azacitidine (Phase I - dose escalation)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess anti-leukemic activity of S64315 in combinaison with azacitidine (Phase I - dose escalation)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Best overall response (BOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess anti-leukemic activity of S64315 in combinaison with azacitidine (Phase I - dose escalation)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess anti-leukemic activity of S64315 in combinaison with azacitidine (Phase I - dose escalation)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Disease-free survival (DFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of S64315 administered in combination with Azacitidine in plasma: Area Under the Curve (AUC) (Phase I - dose escalation)</measure>
    <time_frame>At Day -13, Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 1 Day 5, Cycle 1 Day 7 and Cycle 1 Day 9 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of S64315 administered in combination with Azacitidine in plasma: maximum Concentration (Cmax) (Phase I - dose escalation)</measure>
    <time_frame>At Day -13, Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 1 Day 5, Cycle 1 Day 7 and Cycle 1 Day 9 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acute Myeloid Leukaemia</condition>
  <arm_group>
    <arm_group_label>S64315 (also referred as MIK665) with azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S 64315 (also referred as MIK665) and azacitidine</intervention_name>
    <description>The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.&#xD;
During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days.</description>
    <arm_group_label>S64315 (also referred as MIK665) with azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged ≥ 18 years&#xD;
&#xD;
          2. Patients with cytologically confirmed and documented de novo, secondary or&#xD;
             therapy-related AML as defined by World Health Organization 2016 classification&#xD;
             (Arber, 2016) excluding acute promyelocytic leukaemia (APL, French American-British M3&#xD;
             classification) with: relapsed or refractory disease and without established&#xD;
             alternative therapy, or secondary to MyeloDysplastic Syndrome and without established&#xD;
             alternative therapy or, newly diagnosed AML, not previously treated for AML and who&#xD;
             are not candidate for intensive chemotherapy due to age or comorbidities.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
          4. Adequate haematological, renal and hepatic functions based on the last assessment&#xD;
             performed within 7 days prior to the first Investigational Medicinal Product&#xD;
             administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous myeloproliferative syndrome (MPS).&#xD;
&#xD;
          2. Patients previously treated with any Mcl-1 inhibitor.&#xD;
&#xD;
          3. Patients who have not recovered from toxicity of previous anticancer therapy,&#xD;
             including Grade ≥ 2 toxicity (except alopecia of any grade) according to the National&#xD;
             Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) version&#xD;
             5.0, prior to the first IMP administration.&#xD;
&#xD;
          4. Severe or uncontrolled active acute or chronic infection.&#xD;
&#xD;
          5. Uncontrolled hepatitis B or C infection.&#xD;
&#xD;
          6. Known carriers of HIV antibodies, history of significant liver disease, active acute&#xD;
             or chronic pancreatitis, active central nervous system disease.&#xD;
&#xD;
          7. Troponin &gt; ULN (Upper Limit of reference range) or Troponin T &gt; ULN if Troponin I&#xD;
             cannot be assessed.&#xD;
&#xD;
          8. Clinically significant cardiac dysfunction (including New York Heart Association class&#xD;
             ≥II heart failure, Left Ventricular Ejection Fraction (LVEF) &lt; 50% as assessed by&#xD;
             echocardiography (ECHO) or Multi-Gated Acquisition (MUGA) scan).&#xD;
&#xD;
          9. QT prolongation defined as QTc (QT interval corrected for heart rate) interval&#xD;
             (corrected with Fridericia's formula) &gt; 450 ms for males and &gt; 470 ms for females,&#xD;
             obtained from triplicate 12-lead ECG.&#xD;
&#xD;
         10. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events&#xD;
             such as heart failure, hypokalaemia, congenital long QT syndrome, family history of&#xD;
             long QT syndrome or unexplained sudden death under 40 years of age.&#xD;
&#xD;
         11. Uncontrolled arterial hypertension (systolic blood pressure (SBP) &gt; 150 mmHg or&#xD;
             diastolic blood pressure (DBP) &gt; 95 mmHg).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier Clinical Studies Department</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinical.trial.management@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center Department of Leukemia, Division of Cancer Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Victorian Comprehensive Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital Malignant Haematology &amp; Stem Cell Transplantation Services</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Universitario Valle de Hebrón Servicio de Hematología</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Universitario La Fe Servicio de Hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.servier.com/</url>
    <description>Find Results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukaemia</keyword>
  <keyword>Oncology</keyword>
  <keyword>Mcl-1 inhibitor</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Combination</keyword>
  <keyword>Phase I/II</keyword>
  <keyword>International</keyword>
  <keyword>Safety</keyword>
  <keyword>Maximum tolerated dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.&#xD;
Access can be requested for all interventional clinical studies:&#xD;
used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).&#xD;
where Servier is the Marketing Authorization Holder (MAH).&#xD;
The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.&#xD;
In addition, access can be requested for all interventional clinical studies in patients:&#xD;
sponsored by Servier&#xD;
with a first patient enrolled as of 1 January 2004 onwards&#xD;
for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>https://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>study-level clinical trial data</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

